BridgeBio Oncology Therapeutics Narrows Focus on KRASG12C Inhibitor Combinations
On September 8, BridgeBio Oncology Therapeutics (NASDAQ:BBOT) announced new clinical data for its lead drug candidate BBO-8520 and outlined a strategic shift to focus more narrowly on combination therapies. The company is now prioritizing the use of BBO-8520 with pembrolizumab in previously treated lung cancer patients, alongside other combinations involving earlier-stage assets like BBO-11818 and BBO-10203. The data showed a 75% objective response rate at the highest dose tested when combined with pembrolizumab. This is significant because there are currently no approved targeted therapies for patients whose KRAS G12C-mutated non-small cell lung cancer has progressed after first-line treatment. BridgeBio also reported strong monotherapy results, including a 63% response rate and favorable safety data. Despite these early signs of promise, the company faces financial pressures with its second-quarter net loss nearly doubling year-over-year to $56.5 million due to increased R&D spending as trials expand. While BridgeBio has sufficient cash reserves through at least 2028, key validation points for this strategy are not expected until mid-2027.
Tickers: $BBOT